Gamma frequency neuromodulation is the key to treating dementia, according to the MIT spinout.
The UK group’s disastrous PR strategy could erode trust in its Covid-19 vaccine even further.
A radioligand acquired as part of a $2.1bn deal – and which the sellside believes to be Novartis’s most valuable R&D asset – hits in phase III.
The company placed part of the blame for its mid-stage hearing loss failure on subjects exaggerating their level of hearing loss.
AZD1222 could be rehabilitated by US pivotal trial data showing efficacy of 79%, with no worries about blood clots.
Pivotal data on its closed-loop insulin delivery system look good, but Medtronic remains a threat.
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.